

* NA: not available

Figure S1. Therapeutic indices of CAH derivatives in dedifferentiated SW10 cells. The table (left panel) designated the corresponding concentration of half maximal inhibitory concentration (IC₅₀), half-maximal growth inhibition (GI₅₀), and half maximal effective concentration (EC₅₀) in the SW10 cells with **3a-3l** treatment. The heatmap (right panel) represented the concentration-dependent change of cell viability (%), growth inhibition (%), and cell death (%) of SW10 cells treated with **3a-3l**.






Figure S2. Bindig affinity between protein targets of chalcone (CL) and **3f**. (A) Binding free energy of **3f** and CL with each target was shown as red and blue bars, respectively. (B) Binding potency was compared between **3f** and CL. AR, adrogen receptor; P-gp, P-glycoprotein.



A

Upregulated mRNA



B

Downregulated mRNA





Figure S4. GO molecular function (MF) and cellular component (CC) analysis using upregulated and downregulated DEGs. The GO categories contained the top 5 terms of GO:MF or GO:CC were indicated in (A) and (B), respectively. Top 5 enrichment scores were obtained from the DAVID database.






Figure S6. GO molecular function (MF) and cellular component (CC) analysis using upregulated and downregulated DE miRNAs. The GO categories contained the top 5 terms of GO:MF or GO:CC were indicated in (A) and (B), respectively. Top 5 enrichment scores were obtained from the DAVID database.

Table S1. Primer sequences used in qPCR validation

Gene	Forward (5'-3')	Reverse (5'-3')	bp
<i>TSPYL2</i>	GCAAGTTCATCCAGATGCGA	GTGGTTGAGGAATGCTTTGAC	95
<i>GDF9</i>	GAGTGTGAGCTCCATGACTTT	CCC TTTACAGTATCGAGGGTTG	99
<i>SESN2</i>	CAGCCTATAGCCTCACCTAC	TATCTGATGCCAAAGACGCA	109
<i>CRYAB</i>	GTCAACC TGGATGTGAAGCAC TT	TTCATCCTGGCGCTC TTCAT	102
<i>HSPA1B</i>	CCATTGAGGAGGTGGATTAGGG	ATGACATAGGAAAACAGCAGCA	100
<i>NR4A2</i>	GGGATGGTCAAAGAAGTGGTTCG	GGTCATAGCCGGGTGGAGTC	162
<i>DHRS2</i>	GCCCTACATGGAGAACAGGA	AGC TCCAATGCCAGTG TTCT	138
<i>GAPDH</i>	GGAAGGTGAAGGTCGGAGTCA	GTCATTGATGGCAACAAATATCCACT	101
hsa-miR-1246	AATGGATTTTTGGAGCAGG		
hsa-miR-147b-3p	GTGTGCGGAAATGC TTCTGCT		
hsa-miR-1303	TTTAGAGACGGGGTCTTGCTCT		
hsa-miR-320d	AAAAGCTGGGTTGAGAGGA		
hsa-miR-193a-3p	AACTGGCC TACAAAG TCCCAGT	QuantMir Universal Primer (System Biosciences)	
hsa-miR-23a-3p	ATCACATTGCCAGGGATTCC		
hsa-miR-16-2-3p	CCAATATTACTGTGCTGCTTTA		
hsa-miR-7-5p	TGGAAGACTAGTGATTTTGTGTT		
hsa-miR-425-5p	AATGACACGATCACTCCCGTTGA		
hsa-miR-155-5p	TTAATGCTAATCGTGATAGGGGTT		
human U6	CGCAAGGATGACACGCAAA TTC		

Table S2. Molecular docking between TRPA1 and CAH derivatives

Protein (RCSB ID): TRPA1 (6X2J)			
Ligand	Affinity (kcal/mol)	Ligand	Affinity (kcal/mol)
3a	-7.4	3g	-8.4
3b	-7.2	3h	-7.5
3c	-8.8	3i	-7.2
3d	-7.4	3j	-7.3
3e	-9	3k	-6.6
3f	-9.6	3l	-7.3